Product Description
Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum. (Sourced from: https://www.aquavitpharma.com/post/aquavit-files-ind-for-a-new-botulinum-toxin-with-microchannel-technology-for-palmar-hyperhidrosis)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aquavit
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Hyperhidrosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|